noise dept.
$LAYYYTER
todays bird
we're not kids anymore.
⁂
No title available
tumblr dot com
ojovivo
Sade Olutola
Alisa U Zemlji Chuda
No title available
"I'm Dorothy Gale from Kansas"
Aqua Utopia｜海の底で記憶を紡ぐ
No title available
hello vonnie
oozey mess
TVSTRANGERTHINGS
izzy's playlists!
Misplaced Lens Cap
NASA
seen from Türkiye
seen from Germany
seen from United States
seen from Malaysia
seen from Lithuania
seen from United States
seen from United States
seen from United States
seen from Malaysia
seen from United States
seen from United States
seen from United States
seen from Malaysia
seen from Germany
seen from Germany
seen from United States
seen from Austria
seen from Türkiye
seen from Italy
seen from T1
@murdo99
Promising portents for Portola (PTLA)
Promising portents for Portola (PTLA)
The future looks particularly promising for PTLA. The company plans to file a BLA for the breakthrough therapy andexanet alfa before end 2015. Betrixaban will be close behind with an FDA submission … US 2020 revenue of $1100 is predicted for andexanet alfa, and $1320 for betrixaban.
View On WordPress
PTN Précis (Rexlemestrocel-L)
A review of rexlemestrocel-L from Mesoblast ($MBLTY). Detailed discussion of lumbar and knee osteoarthritis and rexlemestrocel-L potential. Other products discussed include Cartistem (Medipost), TG-C (TissueGene), TPX-100 (OrthoTrophix), and TV-45070 (Teva Pharmaceuticals, $TEVA)
View On WordPress
PTN Précis (Clazakizumab)
Can clazakizumab ($ALDR) compete with other interleukin-6 antagonists? This 2-page review addresses the potential for clazakizumab in the US rheumatoid arthritis market up to 2020. Other products discussed include Actemra (tocilizumab), sarilumab, sirukumab, ALX0061, ALD403, and TEV48125.
View On WordPress
Amyloid-beta inhibitors finally approaching a breakthrough in early AD
Amyloid-beta inhibitors finally approaching a breakthrough in early AD
This comprehensive report provides a detailed overview of US market potential for the following Alzheimer’s disease candidates: solanezumab, verubecestat, aducanumab, ELND005, BAN2401, crenezumab, idalopirdine, sembragiline, AZD3293, CAD106, and E2609. Several other compounds, such as encenicline, T817MA, and LTMX (TRx0237), are also reviewed. Packed full of competitive intelligence insight for…
View On WordPress
Stem cells: an imminent surge in success? This comprehensive research article expands on PharmaTech News' "top ten" of allogeneic ("off-the-shelf") stem-cell products. Clinical trial details are provided and discussed, as are potential dates for topline data releases and FDA approval.
Take beetroot juice for better athletic performance?
Take beetroot juice for better athletic performance?
[corner-ad id=1]
Beetroot juice has benefits
Nitric oxide is an important, natural chemical that improves muscle efficiency and performance, and reduces tiredness, during exercise. Nitrate from leafy, green vegetables in the diet is converted to nitric oxide inside the body. So while we’re all well aware of the need to eat lots of greens, such as lettuce, rocket and spinach, it’s probably not…
View On WordPress
Beetroot juice: if you’re an athlete, give it a try!
Will it be the first fatbusting blockbuster? Sales of fixed-drug combinations of dated constituents (e.g., Vivus’ Qsymia, and Orexigen and Takeda’s Contrave) are decidedly sluggish. Arena and Eisai...
Beloranib will beef-up the obesity space
Beloranib will beef-up the obesity space
Will it be the first fatbusting blockbuster?
Sales of fixed-drug combinations of dated constituents (e.g., Vivus’ Qsymia, and Orexigen and Takeda’s Contrave) are decidedly sluggish.
Arena and Eisai’s Belviq is also underperforming.
Historical safety concerns about the “fen-phen” combination have led to an entrenched mindset against weight-loss pills.
Novo Nordisk’s Saxenda may increase the…
View On WordPress
Beloranib will beef-up the obesity space
Beloranib will beef-up the obesity space
Beloranib will beef-up the obesity space Will it be the first fatbusting blockbuster?
Sales of fixed-drug combinations of dated constituents (e.g., Vivus’ Qsymia, and Orexigen and Takeda’s Contrave) are decidedly sluggish.
Arena and Eisai’s Belviq is also underperforming.
Historical safety concerns about the “fen-phen” combination have led to an entrenched mindset against…
View On WordPress
Will it be the first fatbusting blockbuster? Read more at www.pharmatechnews.com
Will it be the first fatbusting blockbuster?